
    
      An open-label, prospective evaluation of the efficacy of vitamin D supplementation starting 1
      month before and continuing for the duration of combination therapy with pegylated interferon
      alpha (2a or 2b) plus ribavirin in patients with chronic viral hepatitis C genotype 1 or 4,
      nonresponders to a first antiviral therapy.Vitamin D supplementation is started one month
      before antiviral therapy in order to introduce pegylated interferon plus ribavirin in
      patients with optimal vitamin D status
    
  